Product Program year 2025 Source: CMS Open Payments

Zemaira

Biological Pulmonary/Respiratory Diseases

NDC 0053-7201-02

Open in the dashboard

General payments

$448,575

2,390 payments

Research payments

$24,107,912

2,313 payments

Through program year 2025, $448,575 in general payments and $24,107,912 in research payments were reported against Zemaira (Pulmonary/Respiratory Diseases).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $72,677 1,427
2025 Research $836,106 40
2024 General $39,675 10
2024 Research $2,990,006 264
2023 General $28,224 6
2023 Research $6,217,175 569
2022 General $28,675 9
2022 Research $5,196,590 513
2021 General $22,597 168
2021 Research $2,080,389 295
2020 General $191,391 401
2020 Research $6,050,990 507
2019 General $65,335 369
2019 Research $736,658 125

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $415,774 981 payments
  2. Relypsa, Inc. $32,801 1,409 payments
Top recipients General payments · program year 2025
  1. Charlton Strange Critical Care Medicine · Charleston, SC $23,761 33% · 7 payments
  2. Amin Alousi Internal Medicine · Houston, TX $9,566 13% · 7 payments
  3. Wissam Chatila Pulmonary Disease · Philadelphia, PA $2,043 3% · 1 payment
  4. Friedrich Kueppers Pulmonary Disease · Philadelphia, PA $2,043 3% · 1 payment
  5. Nathaniel Marchetti Pulmonary Disease · Philadelphia, PA $2,043 3% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Critical Care Medicine Internal Medicine $25,156 35% · 42 practitioners
  2. Pulmonary Disease Internal Medicine $22,401 31% · 393 practitioners
  3. Internal Medicine $11,112 15% · 44 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $4,292 6% · 109 practitioners
  5. Nurse Practitioner $2,024 3% · 59 practitioners

The top 5 of 26 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. South Carolina $24,379 34% · 21 recipients
  2. Texas $11,091 15% · 46 recipients
  3. Pennsylvania $8,613 12% · 71 recipients
  4. Florida $2,951 4% · 72 recipients
  5. California $2,754 4% · 60 recipients

The top 5 of 38 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,499

Prescriptions dispensed, refills included

Drug cost

$25,399,976

Paid at the pharmacy, in all

Prescribers

162

With 11 or more claims of it

Medicare Part D drugs matched to Zemaira, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Zemaira Alpha-1-Proteinase Inhibitor Same name 162 2,499 $25,399,976

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Eric Rich Pulmonary Disease CO 48 $169,913 None on record
John Tole Allergy/ Immunology AL 47 $48,858 None on record
Charlton Strange Pulmonary Disease SC 37 $456,423 None on record
Colin Swenson Critical Care (Intensivists) GA 37 $373,793 None on record
Rebekah Edwards Nurse Practitioner AZ 36 $355,550 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Zemaira
Billing code Providers Services Paid by Medicare
Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg J0256 6 563,396 $2,155,398

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

2,390 general · 2,313 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record